Intervention Review

You have free access to this content

Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence

  1. Richard P Mattick1,*,
  2. Courtney Breen1,
  3. Jo Kimber1,
  4. Marina Davoli2

Editorial Group: Cochrane Drugs and Alcohol Group

Published Online: 6 FEB 2014

Assessed as up-to-date: 3 DEC 2012

DOI: 10.1002/14651858.CD002207.pub4


How to Cite

Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database of Systematic Reviews 2014, Issue 2. Art. No.: CD002207. DOI: 10.1002/14651858.CD002207.pub4.

Author Information

  1. 1

    University of New South Wales, National Drug and Alcohol Research Centre, Sydney, New South Wales, Australia

  2. 2

    Lazio Regional Health Service, Department of Epidemiology, Rome, Italy

*Richard P Mattick, National Drug and Alcohol Research Centre, University of New South Wales, Sydney, New South Wales, 2052, Australia. R.Mattick@unsw.edu.au.

Publication History

  1. Publication Status: New search for studies and content updated (no change to conclusions)
  2. Published Online: 6 FEB 2014

SEARCH

[Figure 1]
Figure 1. Study flow diagram.
[Figure 2]
Figure 2. Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
[Figure 3]
Figure 3. Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
[Figure 4]
Figure 4. Forest plot of comparison: 1 Flexible dose buprenorphine versus flexible dose methadone, outcome: 1.1 Retention in treatment.
[Analysis 1.1]
Analysis 1.1. Comparison 1 Flexible-dose buprenorphine versus flexible-dose methadone, Outcome 1 Retention in treatment.
[Analysis 1.2]
Analysis 1.2. Comparison 1 Flexible-dose buprenorphine versus flexible-dose methadone, Outcome 2 Morphine-positive urines.
[Analysis 1.3]
Analysis 1.3. Comparison 1 Flexible-dose buprenorphine versus flexible-dose methadone, Outcome 3 Self-reported heroin use.
[Analysis 1.4]
Analysis 1.4. Comparison 1 Flexible-dose buprenorphine versus flexible-dose methadone, Outcome 4 Cocaine-positive urines.
[Analysis 1.5]
Analysis 1.5. Comparison 1 Flexible-dose buprenorphine versus flexible-dose methadone, Outcome 5 Benzodiazepine-positive urines.
[Analysis 1.6]
Analysis 1.6. Comparison 1 Flexible-dose buprenorphine versus flexible-dose methadone, Outcome 6 Criminal activity.
[Analysis 2.1]
Analysis 2.1. Comparison 2 Low-dose buprenorphine versus low-dose methadone, Outcome 1 Retention in treatment.
[Analysis 2.2]
Analysis 2.2. Comparison 2 Low-dose buprenorphine versus low-dose methadone, Outcome 2 Morphine-positive urines.
[Analysis 2.3]
Analysis 2.3. Comparison 2 Low-dose buprenorphine versus low-dose methadone, Outcome 3 Self-reported heroin use.
[Analysis 2.4]
Analysis 2.4. Comparison 2 Low-dose buprenorphine versus low-dose methadone, Outcome 4 Cocaine-positive urines.
[Analysis 3.1]
Analysis 3.1. Comparison 3 Medium-dose buprenorphine versus medium-dose methadone, Outcome 1 Retention in treatment.
[Analysis 3.2]
Analysis 3.2. Comparison 3 Medium-dose buprenorphine versus medium-dose methadone, Outcome 2 Morphine-positive urines.
[Analysis 3.3]
Analysis 3.3. Comparison 3 Medium-dose buprenorphine versus medium-dose methadone, Outcome 3 Self-reported heroin use.
[Analysis 3.4]
Analysis 3.4. Comparison 3 Medium-dose buprenorphine versus medium-dose methadone, Outcome 4 Cocaine-positive urines.
[Analysis 4.1]
Analysis 4.1. Comparison 4 High-dose buprenorphine versus high-dose methadone, Outcome 1 Retention in treatment.
[Analysis 4.2]
Analysis 4.2. Comparison 4 High-dose buprenorphine versus high-dose methadone, Outcome 2 Self-reported heroin use.
[Analysis 5.1]
Analysis 5.1. Comparison 5 Low-dose buprenorphine versus placebo, Outcome 1 Retention in treatment.
[Analysis 5.2]
Analysis 5.2. Comparison 5 Low-dose buprenorphine versus placebo, Outcome 2 Morphine-positive urines.
[Analysis 5.3]
Analysis 5.3. Comparison 5 Low-dose buprenorphine versus placebo, Outcome 3 Cocaine-positive urines.
[Analysis 5.4]
Analysis 5.4. Comparison 5 Low-dose buprenorphine versus placebo, Outcome 4 Benzodiazepine-positive urines.
[Analysis 6.1]
Analysis 6.1. Comparison 6 Medium-dose buprenorphine versus placebo, Outcome 1 Retention in treatment.
[Analysis 6.2]
Analysis 6.2. Comparison 6 Medium-dose buprenorphine versus placebo, Outcome 2 Morphine-positive urines.
[Analysis 6.3]
Analysis 6.3. Comparison 6 Medium-dose buprenorphine versus placebo, Outcome 3 Cocaine-positive urines.
[Analysis 6.4]
Analysis 6.4. Comparison 6 Medium-dose buprenorphine versus placebo, Outcome 4 Benzodiazepine-positive urines.
[Analysis 7.1]
Analysis 7.1. Comparison 7 High-dose buprenorphine versus placebo, Outcome 1 Retention in treatment.
[Analysis 7.2]
Analysis 7.2. Comparison 7 High-dose buprenorphine versus placebo, Outcome 2 Morphine-positive urines.
[Analysis 7.3]
Analysis 7.3. Comparison 7 High-dose buprenorphine versus placebo, Outcome 3 Cocaine-positive urines.
[Analysis 7.4]
Analysis 7.4. Comparison 7 High-dose buprenorphine versus placebo, Outcome 4 Benzodiazepine-positive urines.